BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30833135)

  • 1. Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Mert I; Kumar A; Torres D; Huang Y; McGree ME; Weaver AL; Cliby WA
    Gynecol Oncol; 2019 May; 153(2):238-241. PubMed ID: 30833135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.
    Kim M; Suh DH; Park JY; Paik ES; Lee S; Eoh KJ; Nam JH; Lee YY; Kim JW; Kim S
    J Gynecol Oncol; 2018 Jul; 29(4):e60. PubMed ID: 29770630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
    Chambers LM; Son J; Radeva M; DeBernardo R
    J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
    Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
    Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
    Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
    Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
    Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
    Manning-Geist BL; Sullivan MW; Sarda V; Gockley AA; Del Carmen MG; Matulonis U; Growdon WB; Horowitz NS; Berkowitz RS; Clark RM; Worley MJ
    Ann Surg Oncol; 2021 Oct; 28(11):6705-6713. PubMed ID: 33683525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes.
    Erkilinç S; Karataşli V; Demir B; Çakir İ; Can B; Karadeniz T; Gökçü M; Sanci M
    Int J Gynecol Cancer; 2018 Nov; 28(9):1699-1705. PubMed ID: 30371561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data.
    Irodi A; Rye T; Herbert K; Churchman M; Bartos C; Mackean M; Nussey F; Herrington CS; Gourley C; Hollis RL
    BJOG; 2020 Oct; 127(11):1409-1420. PubMed ID: 32285600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
    J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
    Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
    J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.